Breaking News Instant updates and real-time market news.

VRX

Valeant

$16.13

-1.0301 (-6.00%)

, TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

10:19
11/30/16
11/30
10:19
11/30/16
10:19

Valeant plunges as Salix sale talks said to break down

Shares of Valeant (VRX) are sharply lower in early trading after The Wall Street Journal reported, citing sources, that talks to sell its Salix unit to Japan's Takeda Pharmaceutical (TKPYY) for roughly $10 billion have broken down over price disagreements and other matters. WHAT'S NOTABLE: Valeant is now moving ahead with plans to build the sales force for Salix's Xifaxan, announcing last night that it has initiated a significant sales force expansion to focus on potential primary care physician prescribers of Xifaxan for irritable bowel syndrome with diarrhea, or IBS-D, and Relistor for opioid induced constipation. DEUTSCHE SAID SALE WOULD HAVE BEEN WORTH DOING AT RIGHT PRICE: Weighing on a possible sale of Salix in a note to investors yesterday, Deutsche Bank analyst Gregg Gilbert argued that, on the surface, divesting what could be a "growthy" and durable business is not a no-brainer. However, if Valeant could secure a high enough price to improve its debt burden, he could see why the company would do it, particularly as "maximizing the value of Salix will likely require significant additional resources and management time." Gilbert's early analysis indicates that $10B, plus de-leveraging, would dilute earnings by about 26%-27% in 2018-2021 but boost discounted cash flow value to $32 from $24 and allow Valeant to focus on the durable growth of Bausch + Lomb and its consumer unit. PRICE ACTION: In early trading following the Journal's report, Valeant shares are down 6% to $16.14. Reference Link

VRX

Valeant

$16.13

-1.0301 (-6.00%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

  • 13

    Dec

  • 14

    Dec

  • 16

    Feb

VRX Valeant
$16.13

-1.0301 (-6.00%)

11/18/16
DBAB
11/18/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche still likes near-term setup for Valeant shares
Deutsche Bank analyst Gregg Gilbert said yesterday that he still likes the near-term setup for shares of Valeant Pharmaceuticals after federal prosecutors announced criminal charges against former executive Gary Tanner and the former CEO of Philidor. It is "good to see" that Valeant and other senior executives were not charged, Gilbert told investors in a research note. The charges could be an important step forward as the company and new management team distance themselves from the past, Gilbert wrote. The analyst points out that the bar for 2016 has already been lowered and that new CFO Paul Herendeen thinks of guidance as a commitment. Gilbert keeps a Hold rating on Valeant with a $24 price target. The stock closed yesterday up 12c to $17.98.
11/18/16
ADAM
11/18/16
NO CHANGE
Target $17
ADAM
Hold
Valeant negative headlines remain a risk, says Canaccord
Canaccord analyst Neil Maruoka noted yesterday's headlines regarding criminal charges against a former Valeant executive. He said although the charges are not pertinent to Valeant it underscores the negative headline risk that is associated with owning the shares. Maruoka said the company's lower guidance suggests growth headwinds into next year and believes the company still needs to sell assets to de-lever. Maruoka maintained his Hold rating and $17 price target on Valeant shares.
11/23/16
MZHO
11/23/16
DOWNGRADE
Target $11
MZHO
Underperform
Valeant downgraded to Underperform from Neutral at Mizuho
Mizuho analyst Irina Koffler downgraded Valeant Pharmaceuticals to Underperform, her firm's sell rating equivalent, and cut her price target for the shares to $11 from $25. The drugmaker closed yesterday at $17.83. Koffler believes growth challenges, 2017 guidance risk, legal overhangs and weaker asset divestitures create an unfavorable risk/reward profile. She expects the shares to trend lower over the next 6-12 months.
11/29/16
DBAB
11/29/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche weighs impact on Valeant should Salix be sold
Deutsche Bank analyst Gregg Gilbert hopes to hear closure soon on a potential sale of Salix by Valeant Pharmaceuticals. While a sale is not a "no-brainer" given the unit's growth and durability, a deal could improve Valeant's debt situation and add to its value, Gilbert tells investors in a research note. His preliminary analysis suggests that a sale of Salix for $10B coupled with de-levering would be "significantly" dilutive to earnings but accretive to Valeant's value. His analysis yields earnings dilution of 26%-27% in 2018- 2021 and an increase in the company's theoretical discounted cash flow value to $32 from $24. Gilbert continues to like the near-term setup in shares of Valeant but keeps a Hold rating on the shares with a $24 price target. The pharmaceutical closed yesterday up 44c to $17.44.
TKPYY Takeda Pharmaceutical Co. Ltd.
$20.97

-0.035 (-0.17%)

06/08/16
RHCO
06/08/16
NO CHANGE
RHCO
Ultragenyx collaboration with Takeda 'exceptionally positive,' says SunTrust
After Ultragenyx (RARE) announced a development and commercialization collaboration for rare genetic diseases with Takeda (TKPYY), SunTrust says the deal terms are "exceptionally positive" for Ultragenyx. The firm notes that the latter company will receive both compounds and cash payments from Takeda, while Takeda will only get comemrcial rights in Asia. The firm keeps a Buy rating on Ultragenyx.
07/07/16
UBSW
07/07/16
INITIATION
UBSW
Neutral
Takeda Pharmaceutical initiated with a Neutral at UBS
UBS analyst Atsushi Seki started Takeda with a Neutral rating and Y4,600 price target.
09/14/16
SBSH
09/14/16
NO CHANGE
Target $4
SBSH
Neutral
Citi views Synergy Pharmaceuticals as potential target for Takeda
Citi analyst Liav Abraham calls Synergy Pharmaceuticals (SGYP) the most likely potential target for Takeda Pharmaceutical (TKPYY) among her coverage universe. The Financial Times earlier today reported that Takeda is ready to spend as much as $15B in acquisitions to expand its business in the United States. Abraham has a Neutral rating on Synergy with a $4 price target. The analyst sees Synergy as a potential target given the "extensive resources" needed to commercialize its lead asset, plecanatide, as well as Takdea's presence in the irritable bowel syndrome/chronic idiopathic constipation space. Shares of Synergy are up 6% to $5.18 in early trading.
09/15/16
WELS
09/15/16
NO CHANGE
WELS
Street underestimating potential of PRA Health deal, says Wells Fargo
Wells Fargo believes that the Street is underestimating the potential benefit to PRA Health (PRAH) of its deal with Takeda (TKPYY). The firm expects PRA's bookings over the next year to significantly exceed the industry average, causing 2017 and 2018 consensus estimates for the company to rise. Wells raised its price target on PRA to $65-$67 from $56-$59 and keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

02:30
01/16/18
01/16
02:30
01/16/18
02:30
General news
FX Update: The dollar has settled above yesterday's trend lows »

FX Update: The dollar has…

01:45
01/16/18
01/16
01:45
01/16/18
01:45
General news
FX Action: USD-JPY has lifted to the upper 110.0s »

FX Action: USD-JPY has…

F

Ford

$13.23

0.07 (0.53%)

, FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

20:06
01/15/18
01/15
20:06
01/15/18
20:06
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

F

Ford

$13.23

0.07 (0.53%)

FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

SFTBY

SoftBank

$40.35

-0.705 (-1.72%)

GOOG

Alphabet

$1,122.26

16.74 (1.51%)

GOOGL

Alphabet Class A

$1,130.65

18.6 (1.67%)

TSLA

Tesla

$336.22

-1.73 (-0.51%)

BMWYY

BMW

$36.52

0.835 (2.34%)

TM

Toyota

$137.20

0.29 (0.21%)

GM

General Motors

$44.07

-0.12 (-0.27%)

VLKAY

Volkswagen

$44.34

1.065 (2.46%)

FB

Facebook

$179.37

-8.4 (-4.47%)

AMZN

Amazon.com

$1,305.20

28.52 (2.23%)

AAPL

Apple

$177.09

1.81 (1.03%)

NFLX

Netflix

$221.23

3.99 (1.84%)

VIVHY

Vivendi

$28.42

-1.035 (-3.51%)

BEN

Franklin Resources

$44.53

0.59 (1.34%)

PFE

Pfizer

$36.54

-0.02 (-0.05%)

AMGN

Amgen

$185.04

3.08 (1.69%)

ABBV

AbbVie

$100.34

1.07 (1.08%)

LLY

Eli Lilly

$86.98

0.59 (0.68%)

BMY

Bristol-Myers

$62.81

0.34 (0.54%)

JNJ

Johnson & Johnson

$145.76

0.97 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

  • 18

    Jan

  • 18

    Jan

  • 22

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 25

    Jan

  • 26

    Jan

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 03

    Feb

  • 05

    Feb

  • 06

    Feb

  • 06

    Feb

  • 07

    Feb

  • 08

    Feb

  • 16

    Feb

  • 05

    Mar

  • 18

    Mar

  • 25

    Mar

  • 30

    Apr

  • 17

    May

  • 28

    May

AAPL

Apple

$177.09

1.81 (1.03%)

19:29
01/15/18
01/15
19:29
01/15/18
19:29
Periodicals
China consumer group seeking answers from Apple on slowing iPhones, Reuters says »

A Chinese consumer group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

TWX

Time Warner

$92.05

0.16 (0.17%)

, CMCSA

Comcast

$42.44

-0.16 (-0.38%)

18:52
01/15/18
01/15
18:52
01/15/18
18:52
Hot Stocks
Box Office Battle: 'Jumanji' wins weekend again »

Sony's (SNE)…

TWX

Time Warner

$92.05

0.16 (0.17%)

CMCSA

Comcast

$42.44

-0.16 (-0.38%)

CMCSK

Comcast

SNE

Sony

$50.03

-0.25 (-0.50%)

FOX

21st Century Fox

$36.37

0.57 (1.59%)

FOXA

21st Century Fox

$36.73

0.53 (1.46%)

LGF.A

Lionsgate

$33.71

0.43 (1.29%)

DIS

Disney

$112.47

1.48 (1.33%)

VIAB

Viacom

$33.76

2.95 (9.57%)

VIA

Viacom

$39.10

3.45 (9.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 24

    Jan

  • 24

    Jan

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

FNSR

Finisar

$22.74

0.48 (2.16%)

18:41
01/15/18
01/15
18:41
01/15/18
18:41
Downgrade
Finisar rating change at Goldman Sachs »

Finisar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADTN

Adtran

18:41
01/15/18
01/15
18:41
01/15/18
18:41
Upgrade
Adtran rating change at Goldman Sachs »

Adtran upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

CIEN

Ciena

$21.94

0.06 (0.27%)

18:40
01/15/18
01/15
18:40
01/15/18
18:40
Upgrade
Ciena rating change at Goldman Sachs »

Ciena upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBY

SoftBank

$40.35

-0.705 (-1.72%)

18:36
01/15/18
01/15
18:36
01/15/18
18:36
Periodicals
Auto1 says no need for IPO following SoftBank investment, Reuters reports »

Auto1 said a $561M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$22.07

0.33 (1.52%)

18:32
01/15/18
01/15
18:32
01/15/18
18:32
Hot Stocks
FDA approves Teva's Trisenox injection for Acute Promyelocytic Leukemia »

Teva Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,122.26

16.74 (1.51%)

, GOOGL

Alphabet Class A

$1,130.65

18.6 (1.67%)

18:26
01/15/18
01/15
18:26
01/15/18
18:26
Periodicals
Google relaunching map service in China, Nikkei reports »

Google has relaunched its…

GOOG

Alphabet

$1,122.26

16.74 (1.51%)

GOOGL

Alphabet Class A

$1,130.65

18.6 (1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 18

    Mar

AAPL

Apple

$177.09

1.81 (1.03%)

, TCEHY

Tencent

$56.92

1.565 (2.83%)

18:24
01/15/18
01/15
18:24
01/15/18
18:24
Periodicals
Apple, Tencent reach deal to allow WeChat users dole out tips, WSJ says »

Apple (AAPL) and Tencent…

AAPL

Apple

$177.09

1.81 (1.03%)

TCEHY

Tencent

$56.92

1.565 (2.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

RDS.A

Royal Dutch Shell

$70.88

1.04 (1.49%)

, RDS.B

Royal Dutch Shell

$72.70

0.97 (1.35%)

18:20
01/15/18
01/15
18:20
01/15/18
18:20
Periodicals
Shell acquires stake in solar energy company, Axios reports »

Royal Dutch Shell has…

RDS.A

Royal Dutch Shell

$70.88

1.04 (1.49%)

RDS.B

Royal Dutch Shell

$72.70

0.97 (1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$76.84

1.28 (1.69%)

18:17
01/15/18
01/15
18:17
01/15/18
18:17
Periodicals
Citi to raise pay for women, minorities, Reuters reports »

Citigroup will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

18:10
01/15/18
01/15
18:10
01/15/18
18:10
Periodicals
Fiat Chrysler CEO rules out selling Jeep business, splitting up, WSJ reports »

Fiat Chrysler CEO Sergio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRM

SSR Mining

$8.08

0.13 (1.64%)

18:06
01/15/18
01/15
18:06
01/15/18
18:06
Hot Stocks
SSR Mining reports production of over 370,000 gold equivalent ounces in 2017 »

SSR Mining said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$87.52

0.59 (0.68%)

17:57
01/15/18
01/15
17:57
01/15/18
17:57
Hot Stocks
Exxon Mobil encounters hydrocarbons onshore Papua New Guinea »

ExxonMobil announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEF

Central Fund of Canada Ltd

$13.68

0.23 (1.71%)

17:56
01/15/18
01/15
17:56
01/15/18
17:56
Hot Stocks
Central Fund of Canada Ltd, Sprott announce plan of arrangement closing date »

Central Fund of Canada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NJR

New Jersey Resources

$39.45

-0.1 (-0.25%)

17:52
01/15/18
01/15
17:52
01/15/18
17:52
Hot Stocks
Adelphia files application for certificate of public convenience and necessity »

Following the conclusion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 25

    Jun

NOK

Nokia

$4.87

0.05 (1.04%)

17:49
01/15/18
01/15
17:49
01/15/18
17:49
Hot Stocks
Nokia wins five-year managed services agreement to manage Optus' network »

Nokia and Optus have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSTR

MicroStrategy

$139.75

1.39 (1.00%)

, AMZN

Amazon.com

$1,305.20

28.52 (2.23%)

17:47
01/15/18
01/15
17:47
01/15/18
17:47
Hot Stocks
MicroStrategy announces rollout of MicroStrategy Partner Program »

MicroStrategy (MSTR)…

MSTR

MicroStrategy

$139.75

1.39 (1.00%)

AMZN

Amazon.com

$1,305.20

28.52 (2.23%)

MSFT

Microsoft

$89.60

1.52 (1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 31

    Jan

  • 07

    Feb

  • 18

    Mar

DAR

Darling Ingredients

$19.15

0.41 (2.19%)

17:37
01/15/18
01/15
17:37
01/15/18
17:37
Hot Stocks
Darling Ingredients announces new CFO, Chief Administrative Officer »

Darling Ingredients…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AON

Aon plc

$136.55

1.28 (0.95%)

17:34
01/15/18
01/15
17:34
01/15/18
17:34
Hot Stocks
Aon declares quarterly dividend of 36c per share »

Aon announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBR

KBR

$20.59

0.39 (1.93%)

17:32
01/15/18
01/15
17:32
01/15/18
17:32
Hot Stocks
KBR assures no disruptions on U.K. defense project »

KBR announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

  • 25

    Jun

TRQ

Turquoise Hill

$3.57

0.06 (1.71%)

17:30
01/15/18
01/15
17:30
01/15/18
17:30
Hot Stocks
Turquoise Hill announces that Oyu Tolgoi received $155M Tax Act »

Turquoise Hill Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.